Undisclosed CLEC-1 mAbs / OSE Immunotherapeutics - LARVOL DELTA

First in class Anti-CLEC-1A myeloid checkpoint antibodies for the treatment of solid tumors with monotherapy and combination therapy efficacies (AACR 2025) - "Although their biological activities following interaction with CLEC-1 remain to be fully investigated, we observed that a cell stress induced by radiation or by different chemotherapeutic class agents such as cyclophosphamide (CPA), oxaliplatin, vorinostat and others, increase the expression of CLEC-1 ligand(s) on necrotic and live cells. Moreover, we confirmed also the therapeutic effect of these anti-CLEC-1 antibodies in combination with CPA in the ectopic MC38 model (n=18, 2 independent experiments). Altogether, our results further dissect the mechanism of action of the myeloid checkpoint CLEC-1 in its ability to impair anti-tumor immunity and support its target with antagonist antibody for cancer immunotherapy."

Combination therapy • IO biomarker • Monotherapy • Fibrosarcoma • Liver Cancer • Oncology • Sarcoma • Solid Tumor • TRIM21

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 (GlobeNewswire) - "OSE Immunotherapeutics SA...announced that the latest preclinical data on its novel OSE-CYTOMASK CIS-Demasking cytokine technology and on the CLEC-1 immune checkpoint target, have been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting....The poster presentation titled 'Cis demasking cytokine technology improves therapeutic index of immunocytokine' explains how this technology can make cancer therapies more precise and safer by reducing unwanted immune activity outside of tumors and focusing the treatment on the cancer cells....The poster presentation titled 'First in class Anti-CLEC-1A myeloid checkpoint antibodies for the treatment of solid tumors with monotherapy and combination therapy efficacies' highlights recent positive results from preclinical studies."

Preclinical • Solid Tumor

Anti-tumor in vivo efficacy of different classes of anti-CLEC-1 myeloid checkpoint antibodies in monotherapy and in combination with chemotherapeutic agents (AACR 2024) - "Importantly, high anti-tumor efficacy was observed in combination therapy with cyclophosphamide in MC38 mouse model. Additionally, antagonist anti-CLEC-1 antibodies significantly increase overall survival of Hepa1.6-bearing mice (n=32 for each treatment, p<0.002), as compared to corresponding isotype control treatment in 3 independent experiments. Altogether, our results further dissect the mechanism of action of the myeloid checkpoint CLEC-1 in its ability to impair anti-tumor immunity and support its use as a novel and highly promising anti-CLEC antagonist antibody for cancer immunotherapy."

Combination therapy • Monotherapy • Preclinical • Oncology • TRIM21

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology (GlobeNewswire) - "OSE Immunotherapeutics SA...today announced the publication of novel data in the peer-reviewed Journal of Immunology on a first-in-class research program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy. The academic collaboration conducted with Dr Elise Chiffoleau’s team at the Center for Translational Research in Transplantation and Immunology (2) has led to the identification of CLEC-1 as a checkpoint, a receptor expressed by myeloid cells inhibiting key myeloid cell functions, and T-cell cross-priming and hence limiting anti-tumor immune responses. In the new publication, the collaborative research work confirmed and reinforced the potential of CLEC-1 as a novel myeloid immune checkpoint regulating acute immune responses."

Preclinical • Hematological Malignancies • Oncology

CLEC-1 Restrains Acute Inflammatory Response and Recruitment of Neutrophils following Tissue Injury. (PubMed, J Immunol) - "Interestingly, treatment with an anti-human CLEC-1 antagonist mAb recapitulates the exacerbation of acute immunopathology observed by genetic loss of Clec1a in a preclinical humanized mouse model. To conclude, our results demonstrate that CLEC-1 is a death receptor limiting the acute inflammatory response following injury and represents a therapeutic target to modulate immunity."

Journal • Hepatology • Inflammation • Liver Failure • CCL2 • IL1B • TNFA

Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models (SITC 2023) - "002), as compared to corresponding isotype control treatment. Conclusions Altogether, by shedding new light on the role of CLEC-1/CLEC-1 ligand interactions, our results further dissect the mechanism of action of the myeloid checkpoint CLEC-1 in its ability to impair anti-tumor immunity and support its use as a novel and highly promising target for cancer immunotherapy."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • TRIM21

OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences (Businesswire) - "OSE Immunotherapeutics SA...presents scientific updates in presentations selected for European and American conferences: at the 7th International Cancer Immunotherapy (CICON) Conference in Milan, Italy (September 20 – 23), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA, US (November 1 – 5) and at the 15th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Lisbon, Portugal (November 14 – 16). The communications will feature the latest progress on the Company’s research programs in immuno-oncology, namely CLEC-1 (novel myeloid immune checkpoint), CYTOMASK, a new and innovative CIS-demasking cytokine linker technology, BiCKI^®-IL-7 (bifunctional therapy targeting PD-1 and IL-7), and Tedopi^® (T-cell epitope-based cancer vaccine)."

Clinical data • Oncology

OSE Immunotherapeutics Presents Update on BiCKI IL-7, CLEC-1 and OSE-230 Preclinical Programs in Immuno-Oncology and Immuno-Inflammation At International Conferences (Businesswire) - "OSE Immunotherapeutics...presents scientific updates in oral and poster presentations selected for international conferences: at the Antibody Engineering & Therapeutics Europe 2023 Conference in Amsterdam, Netherlands (June 7), at the FOCIS 2023 Annual Meeting (June 20-23), the 4th Annual Cytokine-Based Drug Development Summit 2023 (June 27-29) and at the 3rd Annual Tumor Myeloid-directed Therapies Summit 2023 (July 18-20) in Boston, US. The communications feature the latest research on pre-IND programs for BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7), CLEC-1 (new myeloid immune checkpoint) in immuno-oncology and for OSE-230 (first pro-resolutive monoclonal antibody) in chronic inflammation."

Preclinical • Burkitt Lymphoma • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Inflammation • Liver Cancer • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • Thoracic Cancer

OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update (Businesswire) - "A STRONG GLOBAL INTELLECTUAL PROPERTY STRATEGY: (i) OSE-172: Four patents (United States, Japan, Korea and ARIPO (Africa)) covering anti-SIRPα antibodies, until 2036-2037; (ii) OSE-279: Six patents (United States, Japan, Korea, China, Mexico and Colombia) for OSE-279 and its use in cancer treatment, until 2039; (iii) CLEC-1: Three patents (United States, Japan and Israel) covering CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy, until 2037."

Patent • Oncology

TRIM21 is a novel endogenous partner of the inhibitory myeloid checkpoint CLEC-1 involved in tumor antigen cross-presentation (AACR 2023) - "Antagonist anti-CLEC-1 or anti-TRIM21 antibodies are therefore being evaluated to further confirm the involvement of the newly identified CLEC-1 interaction with TRIM21 in the regulation of CLEC-1’s function as an inhibitory myeloid checkpoint. Altogether our data highlight the CLEC-1/TRIM21 axis as a new target for cancer immunotherapy."

IO biomarker • Brain Cancer • CNS Tumor • Colorectal Cancer • Gastrointestinal Cancer • Glioma • Hepatocellular Cancer • Lung Cancer • Mesothelioma • Oncology • Pancreatic Cancer • Solid Tumor • TRIM21

CLEC-1 inhibitory myeloid checkpoint blockade enhances antitumor responses and tumor phagocytosis by macrophages (AACR 2023) - "Moreover, the synergy with chemotherapy treatment (cyclophosphamide, gemcitabine) in the MC38 model of colon adenocarcinoma in Clec1a deficient animals significantly enhanced complete responses. Mechanistically, the in vivo phagocytosis of tumor cells (Hepa1.6 and MCA101) by macrophages was enhanced in CLEC-1 deficient animals compared to WT animals. Altogether, our results demonstrate that CLEC-1 acts as a novel immune checkpoint in myeloid cells and highlight its high potential as a target for innovative immunotherapy in oncology."

Checkpoint block • Checkpoint inhibition • Colon Cancer • Colorectal Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Mesothelioma • Oncology • Solid Tumor • PD-1

OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology (Businesswire) - "TRIM21, an intra-cellular Fc receptor and E3 ubiquitin ligase, is identified as a novel interaction partner for CLEC-1...The research demonstrated the functional relevance of CLEC-1 interaction with its ligand. High TRIM21 expression is predictive of worse overall survival in patients with hepatocellular carcinoma, pancreatic cancer, or glioma. Mechanistically, CLEC-1 inhibition enhances the capacity of dendritic cells to cross-present tumor antigens to T lymphocytes, a process known to be regulated by TRIM21 through its E3 ubiquitin ligase activity. Antagonist anti-CLEC-1 or anti-TRIM21 antibodies are therefore being evaluated to further confirm the involvement of the newly identified CLEC-1 interaction with TRIM21 in the regulation of CLEC-1’s function as an inhibitory myeloid checkpoint."

Preclinical • Gastrointestinal Cancer • Glioma • Hepatocellular Cancer • Liver Cancer • Oncology • Pancreatic Cancer

OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology (Businesswire) - "OSE Immunotherapeutics SA...presented two additional posters reporting the latest research updates on CLEC-1 (new myeloid immune checkpoint), from its Myeloid platform, at the 2023 American Association for Cancer Research (AACR) Annual Meeting held in Orlando (Florida) on April 14-19....The findings presented also revealed a previously unrecognized function for CLEC-1 in myeloid cells as a specific sensor of non-homeostatic cell death. The data showed that the absence of CLEC-1 suppresses tumor growth and hinders immunosuppressive tumor microenvironment."

Preclinical • Oncology • Solid Tumor

OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology (Businesswire) - "OSE Immunotherapeutics SA...announced it will be presenting five posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting....Four communications will feature the latest research on pre-IND programs for the pioneering Myeloid and BiCKI^® platforms, namely presentations on CLEC-1 (new myeloid immune checkpoint) and BiCKI^®-IL7 (new bifunctional therapy targeting PD-1 and IL-7), and OSE-127 (anti-IL-7 receptor antagonist) hematology program. A fifth communication will feature biomarker analyses on BI 765063 (anti-SIRPα monoclonal antibody on CD47/SIRPα pathway) from the ongoing Phase 1 clinical trial in advanced solid tumors."

Biomarker • P1 data • Preclinical • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Solid Tumor

OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’ (Businesswire) - "OSE Immunotherapeutics SA...announced the publication of data in the peer-reviewed journal Science Advances on a first-in-class preclinical program with CLEC-1, its novel myeloid immune checkpoint target for cancer immunotherapy...Importantly, CLEC-1 blockade using monoclonal antibody treatment demonstrates robust anti-tumor activity, also by reinvigorating the tumor immune microenvironment in several preclinical oncology models, thereby faithfully recapitulating the effect of CLEC-1 genetic deletion in the context of human CLEC-1-expressing mice. Proprietary anti-CLEC-1 mAbs increase survival in monotherapy in orthotopic model of hepatocellular carcinoma while combination with chemotherapy increases preclinical tumor eradication in colon carcinoma model."

Preclinical • Oncology • Solid Tumor

CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy. (PubMed, Sci Adv) - "We identified antihuman CLEC-1 antagonist antibodies able to enhance antitumor immunity in CLEC-1 humanized mice. Together, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy."

Journal • Immune Modulation • Inflammation • Oncology • TRIM21

Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation (SITC 2022) - "Importantly, we generated anti-human CLEC-1 antagonist antibodies able to enhance anti-tumor immunity in CLEC-1 humanized mice. Conclusions Altogether, our results demonstrate that CLEC-1 acts as an immune checkpoint in myeloid cells and support CLEC-1 as a novel target for cancer immunotherapy."

IO biomarker • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs (Businesswire) - "CLEC-1 program in Immuno-Oncology (SITC 2022)....The latest data presented at the SITC 2022 show the ability of CLEC-1 to sense dead or stress tumor cells through the identification of a CLEC-1 protein ligand (CLEC-1 ligand) over-expressed in cancer cells. Mechanistically, CLEC-1’s expression by dendritic cells controls the cross-presentation of dead-cell tumor associated antigens and hence CD8+ T-cell cross-priming. Reversely, the absence of CLEC-1 increases the phagocytosis of tumor cells by macrophages in vivo. Proprietary anti-CLEC-1 mAbs increase survival in monotherapy in orthotopic model of hepatocellular carcinoma while combination with chemotherapy increases preclinical tumor eradication in colon carcinoma model."

Preclinical • Colon Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

OSE Immunotherapeutics Presents Update on BiCKI-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences (Businesswire) - "OSE Immunotherapeutics SA...announced that three posters have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting which will be held in person and virtually in Boston, MA, November 8 – 12. The posters will feature the latest preclinical data on the Company’s pioneering drug discovery BiCKI® and Myeloid platforms and including BiCKI®-IL-7 (bifunctional therapy targeting PD-1 and IL-7) and CLEC-1 (new myeloid immune checkpoint). The Company was also invited for an oral presentation at the Macrophage-directed Therapies Summit of its CLEC-1 program (Boston, October 2022)."

Preclinical • Oncology

"OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences https://t.co/NsQE78SVHH" (@NewsFromBW)

Oncology

OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results (Businesswire) - "A newly formed SAB combining the expertise of renowned scientific and international key-opinion leaders in the fields of immunology, immuno-oncology, inflammation and immunotherapy...The SAB includes...Dr. Jennifer Wargo...."

OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Boston (GlobeNewswire) - "The presentations will focus on: CLEC-1, a novel checkpoint to regulate the antigen cross-presentation properties of dendritic cells; The identification and validation of novel immune checkpoint targets and development of their antagonists as an innovation in cancer immunotherapy to enhance myeloid cells and promote antigen presentation to bridge the innate and adaptative immune system; How the SIRPα-CD47 axis stimulates macrophages to recruit the adaptive immune arm via chemoattraction, and inhibition of this pathway may avoid T cell exclusion in synergy with T cell immune checkpoint and clinical translation."

Clinical • Preclinical • Hematological Malignancies • Oncology

OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy (GlobeNewswire) - "OSE Immunotherapeutics SA...announced the grant of a new patent from the European Patent Office (EPO) strengthening the protection covering its novel myeloid cell immune checkpoint target, CLEC-1 (a C-type lectin receptor), and its use in cancer treatment. This patent provides a protection until 2037....'The patent has been extended to other major territories with the notice of allowance already granted in the United States and the patent granted in Japan'."

Patent • Oncology

Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology (SITC 2021) - "Results Using newly developed anti-human CLEC-1 monoclonal antibodies (mAbs), we found that antagonist anti-CLEC-1 mAbs with the capacity to block CLEC-1/CLEC-1Ligand interaction, as opposed to non-antagonist CLEC-1 mAbs, increase the phagocytosis of CLEC-1Ligand-positive human tumor cells by human macrophages, in particular when opsonized by tumor-associated antigen mAbs (Rituximab, Cetuximab, Trastuzumab) or with anti-CD47 mAb (Magrolimab)...CLEC1 KO mice also illustrate significant eradication of MC38 colorectal tumors in combination with chemotherapy promoting CLEC-1Ligand expression by tumor cells (n=16 with Gemcitabine or n=11 with Cyclophosphamide)...Finally, we recently generated human CLEC-1 knock-in mice expressing the extracellular human CLEC1 domain fused to the intracellular mouse CLEC1 tail and confirmed preclinical efficacy in vivo with anti-human CLEC1 antagonist mAb in monotherapy in the orthotopic HCC model. Conclusions These data illustrate that CLEC-1..."

IO biomarker • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CD8 • PD-1

OSE Immunotherapeutics Presented the First Positive Preclinical Efficacy Data on CLEC-1, a Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy (GlobeNewswire) - "OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first positive preclinical efficacy data on its novel myeloid cell immune checkpoint target, CLEC-1 (a C-type lectin receptor), at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting in Washington D.C. held in-person and virtually on November 10 – 14, 2021...CLEC-1 is a C-type lectin receptor with demonstrated potential to inhibit the functions of myeloid cells and to block anti-tumor responsiveness of T-lymphocytes. Myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T-lymphocytes."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology